CXCL14/BRAK Antibody (135633) [Alexa Fluor® 405]

• Reactivity: Mu
• Applications: WB
• Clone: 135633
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 405

CXCL14/BRAK Antibody (135633) [Alexa Fluor® 405] Summary

• Immunogen: E. coli-derived recombinant mouse CXCL14/BRAK
  Ser23-Glu99
  Accession # NP_062514
• Specificity: Detects mouse CXCL14 in direct ELISAs and Western blots. In direct ELISAs, this antibody shows 100% cross-reactivity with recombinant human (rh) CXCL14 and no cross-reactivity with rhCXCL1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16, rmCXCL4, 7, 1
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL14/BRAK Antibody (135633) [Alexa Fluor® 405]

• BMAC
• Bolekine
• BRAK
• BRAKKEC
• chemokine (C-X-C motif) ligand 14
• Chemokine BRAK
• CXCL14
• CXC-X3
• member 14 (BRAK)
• MIP-2 gamma
• MIP2G
• MIP-2G
• NJACKec
• SCYB14MGC10687
• Small-inducible cytokine B14

Background

CXCL14/BRAK, also named MIP-2 gamma, KEC (kidney-expressed chemokine), and BMAC (B cell and monocyte-activating chemokine), is a member of the CXC chemokine superfamily (1 - 5). The deduced 99 amino acid (aa) residue precursor has a 22 aa putative signal peptide that is cleaved to produce the 77 aa mature protein. Mature human and mouse CXCL14 differ by only 2 residues. Mouse CXCL14 shares approximately 30% aa sequence identity with mouse MIP-2. Unlike MIP‑2, CXCL14 lacks the ELR domain preceding the CXC motif. CXCL14 transcripts are constitutively expressed at high levels in the basal layer of epidermal keratinocytes and dermal fibroblasts of skin tissues as well as lamina propria cells in normal intestinal tissues. CXCL14 has been shown to be a highly selective chemoattractant for monocytes that have been treated with prostaglandin E₂ or forskolin, agents that activate adenylate cyclase. CXCL14 has been proposed to be important in regulating the trafficking of macrophage precursor to regions in skin and mucosal tissues that support their development. Consistent with this hypothesis, macrophages were frequently found to co-localize with CXCL14-producing cells in the dermis and lamina propria.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.